Format

Send to

Choose Destination
Expert Opin Drug Deliv. 2014 Jul;11(7):1103-11. doi: 10.1517/17425247.2014.918101. Epub 2014 Jun 4.

The administration of L-thyroxine as soft gel capsule or liquid solution.

Author information

1
University of Messina, Endocrinology, Department of Clinical & Experimental Medicine , Viale Gazzi, Padiglione H, 4 piano, 98125 Messina , Italy +39 090 221 3560 ; +39 090 221 3518 ; roberto.vita@yahoo.it.

Abstract

INTRODUCTION:

Levothyroxine (l-T4) is the mainstay of treating hypothyroidism. The tablet is the traditional formulation of l-T4. Tablet l-T4 malabsorption results from either hindered gastric dissolution of the tablet or binding of l-T4 by sequestrants in the intestinal lumen.

AREAS COVERED:

This review provides an overview of the pharmacokinetics of l-T4 formulations available in the market: the tablet, the soft gel capsule and the oral solution. We review literature on the new formulations and anticipate the areas of future research.

EXPERT OPINION:

Failure of l-T4 treatment to reach target serum thyroid-stimulating hormone levels generally prompts the physicians to increase l-T4 daily dose. In vitro studies have shown that the soft gel capsule releases the active ingredient more consistently at varying pH than the tablet. In addition, in vivo studies have confirmed the in vitro data and have demonstrated that both the soft gel capsule and the liquid formulation are capable to solve tablet l-T4 malabsorption caused by certain drugs, bariatric surgery or coffee. These new formulations may be attractive also for patients who cannot/do not want to change their (improper) habits of l-T4 ingestion. Finally, the oral solution l-T4 could be suitable for patients who cannot swallow the solid formulations.

KEYWORDS:

drugs; intestinal absorption; levothyroxine; oral solution; soft gel capsule

PMID:
24896369
DOI:
10.1517/17425247.2014.918101
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center